WINTON GROUP Ltd Buys Shares of 9,088 Cytokinetics, Incorporated $CYTK

Posted by George Bondi on Sep 15th, 2026

WINTON GROUP Ltd bought a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 9,088 shares of the biopharmaceutical company’s stock, valued at approximately $774,000.

A number of other hedge funds have also made changes to their positions in the stock. Integrated Wealth Concepts LLC acquired a new stake in shares of Cytokinetics during the second quarter worth approximately $36,000. Rockefeller Capital Management L.P. grew its position in Cytokinetics by 842.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 641 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 573 shares in the last quarter. Clearstead Advisors LLC increased its stake in Cytokinetics by 97.1% in the 4th quarter. Clearstead Advisors LLC now owns 670 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 330 shares during the period. Western Wealth Management LLC acquired a new position in Cytokinetics in the 1st quarter valued at approximately $53,000. Finally, EverSource Wealth Advisors LLC lifted its position in Cytokinetics by 55.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,548 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 549 shares in the last quarter.

Cytokinetics Stock Performance

Shares of CYTK opened at $72.45 on Tuesday. The firm has a market cap of $9.02 billion, a PE ratio of -10.03 and a beta of 0.36. The firm’s 50 day moving average price is $77.79 and its 200 day moving average price is $72.75. Cytokinetics, Incorporated has a twelve month low of $47.22 and a twelve month high of $88.31.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.13. The business had revenue of $28.62 million during the quarter, compared to analyst estimates of $17.59 million. Cytokinetics’s revenue was down 57.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.12) earnings per share. On average, sell-side analysts anticipate that Cytokinetics, Incorporated will post -5.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Citigroup reissued a “market outperform” rating on shares of Cytokinetics in a research note on Friday, August 7th. Citizens Jmp upped their price target on shares of Cytokinetics from $105.00 to $110.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. Royal Bank Of Canada cut their price objective on Cytokinetics from $117.00 to $112.00 and set an “outperform” rating for the company in a report on Friday, August 7th. JPMorgan Chase & Co. lifted their price objective on Cytokinetics from $97.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th. Finally, Morgan Stanley raised Cytokinetics from an “overweight” rating to a “buy” rating in a research report on Tuesday, September 1st. Eighteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Cytokinetics has an average rating of “Moderate Buy” and a consensus price target of $103.37.

Check Out Our Latest Research Report on Cytokinetics

Insider Buying and Selling at Cytokinetics

In other Cytokinetics news, CEO Robert Blum sold 7,500 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $84.92, for a total transaction of $636,900.00. Following the transaction, the chief executive officer directly owned 377,830 shares of the company’s stock, valued at $32,085,323.60. This represents a 1.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director B. Parshall sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $71.48, for a total value of $357,400.00. Following the transaction, the director owned 10,784 shares in the company, valued at approximately $770,840.32. This trade represents a 31.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 104,246 shares of company stock worth $8,257,867 over the last quarter. Company insiders own 2.60% of the company’s stock.

Cytokinetics Company Profile

(Free Report)

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. The company applies expertise in muscle physiology and contractility to develop potential treatments for cardiovascular and neuromuscular diseases.

Its leading programs include aficamten, an investigational cardiac myosin inhibitor being developed for conditions involving abnormal heart-muscle contraction, including hypertrophic cardiomyopathy.